Charles River Laboratories Coverage Initiated by Analysts at Sterne Agee (CRL)

Research analysts at Sterne Agee started coverage on shares of Charles River Laboratories (NYSE: CRL) in a report released on Tuesday, TheFlyOnTheWall.com reports. The firm set a “buy” rating and a $56.00 price target on the stock. Sterne Agee’s price objective points to a potential upside of 32.48% from the company’s current price.

The analysts wrote, “In our view, CRL can be characterized as a dominant player within businesses that possess high barriers to entry. With innovative product and service offerings offered at competitive prices, we believe large biopharmaceutical companies seeking to variable-ize cost structures will look to CRL as a provider of choice. We are re-initiating coverage of CRL with a Buy rating and $56 price target.”

A number of other analysts have also recently weighed in on CRL. Analysts at Barclays Capital raised their price target on shares of Charles River Laboratories from $38.00 to $41.00 in a research note to investors on Monday, June 3rd. They now have an “equal weight” rating on the stock. Separately, analysts at Raymond James downgraded shares of Charles River Laboratories from a “market perform” rating to an “underperform” rating in a research note to investors on Friday, May 31st. They noted that the move was a valuation call. Finally, analysts at ISI Group cut their price target on shares of Charles River Laboratories from $45.50 to $44.50 in a research note to investors on Thursday, May 2nd. They now have a “neutral” rating on the stock.

Two analysts have rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company’s stock. Charles River Laboratories currently has an average rating of “Hold” and a consensus price target of $45.45.

Shares of Charles River Laboratories (NYSE: CRL) traded up 0.57% during mid-day trading on Tuesday, hitting $42.51. Charles River Laboratories has a 52 week low of $31.48 and a 52 week high of $46.90. The stock’s 50-day moving average is currently $43.3. The company has a market cap of $2.084 billion and a P/E ratio of 21.17.

Charles River Laboratories (NYSE: CRL) last issued its quarterly earnings data on Wednesday, May 1st. The company reported $0.69 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.71 by $0.02. The company had revenue of $291.20 million for the quarter, compared to the consensus estimate of $294.53 million. During the same quarter in the previous year, the company posted $0.70 earnings per share. The company’s revenue for the quarter was up 1.8% on a year-over-year basis. Charles River Laboratories has set its FY13 guidance at $2.80-2.90 EPS. Analysts expect that Charles River Laboratories will post $2.82 EPS for the current fiscal year.

Charles River Laboratories International, Inc. (NYSE: CRL) is a global provider of solutions, which accelerate the early-stage drug discovery and development process.

The Fly On The Wall



Latest News

Ally Financial  Releases Quarterly  Earnings Results, Beats Expectations By $0.03 EPS
Ally Financial Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS
Mastercard Inc  Shares Acquired by Legacy Bridge LLC
Mastercard Inc Shares Acquired by Legacy Bridge LLC
Kelman Lazarov Inc. Has $1.50 Million Holdings in Atmos Energy Co.
Kelman Lazarov Inc. Has $1.50 Million Holdings in Atmos Energy Co.
Kelman Lazarov Inc. Raises Stake in iShares Core S&P Small-Cap ETF
Kelman Lazarov Inc. Raises Stake in iShares Core S&P Small-Cap ETF
Celanese Co.  Shares Sold by Legacy Bridge LLC
Celanese Co. Shares Sold by Legacy Bridge LLC
Legacy Bridge LLC Decreases Stock Position in ConocoPhillips
Legacy Bridge LLC Decreases Stock Position in ConocoPhillips


© 2006-2019 Ticker Report